Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors

Gene Therapy

Volumn 4, Issue 3, 1997, Pages 189-198

  Feldman, L J ^a   Pastore, C J ^a   Aubailly, N ^b   Kearney, M ^a   Chen, D ^a   Perricaudet, M ^b   Steg, P G ^c   Isner, J M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c PO B   (France)

Author keywords

Adenovirus; Gene therapy; Poloxamer 407; Restenosis; Smooth muscle cells; Transfection

Indexed keywords

BETA GALACTOSIDASE; POLOXAMER;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DNA TRANSFECTION; EXPRESSION VECTOR; GENE TARGETING; GENE TRANSFER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0030994739     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300382     Document Type: Article

References (38)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
2. Chang MW et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522.
3. Isner JM, Feldman LJ. Gene therapy for arterial disease. Lancet 1994; 344: 1653-1654.
4. Schneider MD, French BA. The advent of adenovirus. Gene therapy for cardiovascular disease. Circulation 1993; 88: 1937-1942.
5. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995; 91: 541-548.
6. Feldman LJ, Tahlil O, Steg PG. Perspectives of arterial gene therapy for the prevention of restenosis. Cardiovasc Res 1996; 32: 194-207.
7. Lee SW et al. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73: 797-807.
8. Guzman R et al. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 1993; 88: 2838-2848.
9. Willard JE et al. Genetic modification of the vessel wall. Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994; 89: 2190-2197.
10. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
11. Guzman RJ et al. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994; 91: 10732-10736.
12. Steg PG et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994; 90: 1648-1656.
13. French BA et al. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994; 90: 2402-2413.
14. Feldman LJ et al. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995; 95: 2662-2671.
15. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity. Circulation 1995; 91: 2407-2414.
16. Chang MW et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268.
17. Casscells W, Willerson JT. Amphotropic but not atherotropic: another caveat for adenoviral gene therapy. J Clin Invest 1995; 95: 2425-2426.
18. Feldman LJ et al. Efficient percutaneous adenovirus-mediated arterial gene transfer using a channeled angioplasty balloon catheter. Circulation 1994; 90 (Suppl. I): I-20 (Abstr. No. 95).
19. March KL, Wilensky RL, Hathaway DR. Novel drug and device combinations for targeted prevention of restenosis. Cardiovasc Intervent 1992; 2: 11-26.
20. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994; 23: 1234-1244.
21. Newman KD et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
22. March K, Madison JE, Trapnell BC. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther 1995; 6: 41-53.
23. Illum L, Davis SS. Targeting of colloidal particles to the bone marrow. Life Sci 1987; 40: 1553-1560.
24. Moghimi SM et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 1991; 177: 861-866.
25. Porter CJ, Moghimi SM, Illum L, Davis SS. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer 407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett 1992; 305 62-66.
26. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intra-peritoneal injection in mice. Pharm Res 1992; 9: 425-434.
27. Pec EA, Wout ZG, Johnson TP. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-630.
28. Simons M et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
29. Indolfi C et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995; 1: 541-545.
30. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993; 72: 1132-1138.
31. Muller DWM et al. Catheter-mediated pulmonary vascular gene transfer and expression. Circ Res 1994; 75: 1039-1049.
32. Quantin B, Stratford-Perricaudet LD, Tajbakhsh S, Mandel J-L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992; 89: 2581-2584.
33. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-630.
34. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
35. Clowes A, Reidy M, Clowes M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
36. Sanes JR, Rubenstein JLR, Nicolas JF. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 1986; 5: 3133-3142.
37. Lederc G et al. Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest 1992; 90: 936-944.
38. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.